Haemonetics Corporation (NYSE:HAE) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Haemonetics Corporation (NYSE:HAE) has received an average rating of "Moderate Buy" from twelve brokerage firms, with one sell, one hold, nine buy, and one strong buy recommendation.
• The stock's average target price among analysts is $85.18, with recent target changes including a decrease from Citigroup to $90.00 and Raymond James from $105.00 to $78.00.
• Haemonetics reported $1.10 EPS for its last quarter, surpassing the consensus estimate, but revenue declined 4.4% year-over-year at $321.39 million.

Shares of Haemonetics Corporation (NYSE:HAE - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twelve ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $85.1818.

A number of equities analysts have commented on HAE shares. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $62.00 price objective (down from $85.00) on shares of Haemonetics in a research report on Friday, August 8th. Mizuho reduced their target price on shares of Haemonetics from $90.00 to $70.00 and set an "outperform" rating for the company in a research report on Friday, August 8th. JMP Securities reissued a "market outperform" rating and issued a $100.00 target price on shares of Haemonetics in a research report on Tuesday, May 20th. Citigroup raised shares of Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 target price for the company in a research report on Wednesday, July 9th. Finally, Robert W. Baird began coverage on shares of Haemonetics in a research report on Thursday, June 26th. They issued an "outperform" rating and a $87.00 target price for the company.

Haemonetics Trading Down 0.4%

Haemonetics stock traded down $0.24 during midday trading on Thursday, hitting $54.30. 47,876 shares of the stock were exchanged, compared to its average volume of 807,101. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04. Haemonetics has a 52 week low of $50.68 and a 52 week high of $94.99. The stock has a market capitalization of $2.62 billion, a PE ratio of 16.60, a P/E/G ratio of 1.01 and a beta of 0.39. The company has a fifty day simple moving average of $67.64 and a two-hundred day simple moving average of $66.04.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.01 by $0.09. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The company had revenue of $321.39 million for the quarter, compared to the consensus estimate of $305.12 million. During the same period last year, the company earned $1.02 earnings per share. The firm's revenue was down 4.4% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. Equities research analysts anticipate that Haemonetics will post 4.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Norges Bank acquired a new stake in Haemonetics during the 2nd quarter valued at approximately $36,822,000. SG Capital Management LLC increased its position in Haemonetics by 92.5% during the 2nd quarter. SG Capital Management LLC now owns 906,892 shares of the medical instruments supplier's stock valued at $67,663,000 after purchasing an additional 435,660 shares during the period. Citigroup Inc. grew its stake in shares of Haemonetics by 87.3% in the 1st quarter. Citigroup Inc. now owns 625,565 shares of the medical instruments supplier's stock valued at $39,755,000 after buying an additional 291,574 shares during the period. AQR Capital Management LLC grew its position in Haemonetics by 157.9% in the 2nd quarter. AQR Capital Management LLC now owns 450,248 shares of the medical instruments supplier's stock valued at $33,390,000 after purchasing an additional 275,683 shares during the period. Finally, River Road Asset Management LLC boosted its holdings in Haemonetics by 18.7% during the 2nd quarter. River Road Asset Management LLC now owns 1,655,676 shares of the medical instruments supplier's stock worth $122,586,000 after acquiring an additional 260,624 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.